Incyte snuck out some bad news Friday night: Afterhours, the Wilmington, Delaware-based biopharma said it had been hit with an FDA complete response letter for | Incyte snuck out some bad news Friday night: Afterhours, the Wilmington, Delaware-based biopharma said it had been hit with an FDA complete response letter for its experimental checkpoint inhibitor retifanlimab.
